Bristol-Myers Squibb (NYSE:BMY) and Pfizer (NYSE:PFE) will offer a 40% discount on Eliquis, a blood thinner, starting September 8th, through a direct-to-consumer service, the companies said on Thursday.
The companies, which have a joint venture that markets Eliquis, said the new service will allow uninsured or underinsured patients to buy the pill at more than 40% off the current list price.
The program will provide direct shipping to patients across all 50 states and Puerto Rico, offering an additional, simplified option for accessing Eliquis and full transparency into the associated costs.
“The BMS-Pfizer Alliance is committed to increasing patient access and affordability, which is why we are launching this direct-to-patient offering for Eliquis,” said Bristol-Myers Chief Executive Christopher Boerner.
